ArticleThyroid research2013
The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association.
Article in Thyroid research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines.Frontiers in endocrinology · 2022Article
- Variability in Medullary Thyroid Carcinoma inFrontiers in endocrinology · 2020Article
- Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?International journal of molecular sciences · 2017Review
- Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.Scientific reports · 2017Article
- The rare intracellular RET mutation p.S891A in a Chinese Han family with familial medullary thyroid carcinoma.Journal of biosciences · 2014Article
- Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).Langenbeck's archives of surgery · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the 9th ETA-CRN Meeting (September 2009, Lisbon) some recommendations from the American Thyroid Association (ATA) guidelines for the management of medullary thyroid cancer (MTC) were discussed by an European Panel of Experts (EPE). Among the 12 ATA recommendations related to hereditary MTC and to the optimal range of RET mutations to be tested (recommendations 1-5 and 9-15), 7 were shared and 5 were not shared by the EPE. In the present paper, the related comments and suggestions will be reported and discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.